Clinical and economic studies of eptifibatide in coronary stenting

Abstract: Platelet adhesion and aggregation at the site of coronary stenting can have catastrophic clinical and economic consequences. Therefore, effective platelet inhibition is vital during and after percutaneous coronary intervention. Eptifibatide is an intravenous antiplatelet agent that blocks the final common pathway of platelet aggregation and thrombus formation by binding to glycoprotein IIb/IIIa receptors on the surface of platelets. In clinical studies, eptifibatide was associated with a significant reduction of mortality, myocardial infarction, or target vessel revascularization in patients with acute coronary syndrome undergoing percutaneous coronary intervention. However, recent trials conducted in the era of dual antiplatelet therapy and newer anticoagulants failed to demonstrate similar results. The previously seen favorable benefit of eptifibatide was mainly offset by the increased risk of bleeding. Current American College of Cardiology/American Heart Association guidelines recommend its use as an adjunct in high-risk patients who are undergoing percutaneous coronary intervention with traditional anticoagulants (heparin or enoxaparin), who are not otherwise at high risk of bleeding. In patients receiving bivalirudin (a newer safer anticoagulant), routine use of eptifibatide is discouraged except in select situations (eg, angiographic complications). Although older pharmacoeconomic studies favor eptifibatide, in the current era of P2Y₁₂ inhibitors and newer safer anticoagulants, the increased costs associated with bleeding make the routine use of eptifibatide an economically nonviable option. The cost-effectiveness of eptifibatide with the use of strategies that decrease the bleeding risk (eg, transradial access) is unknown. This review provides an overview of key clinical and economic studies of eptifibatide well into the current era of potent antiplatelet agents, novel safer anticoagulants, and contemporary percutaneous coronary intervention.

Keywords: eptifibatide, Integrilin®, glycoprotein IIb/IIIa inhibitors, percutaneous coronary intervention, acute coronary syndrome, coronary artery disease, cost-effectiveness

Introduction

Compared with coronary angioplasty, percutaneous coronary intervention (PCI) with stenting remarkably improves survival in patients presenting with acute coronary syndrome (ACS). However, stenting causes platelet activation and aggregation that can lead to catastrophic thrombotic complications. Significant advances in stent technology and antiplatelet therapy have nevertheless reduced early (0 to 30 days) stent thrombosis to less than 1%. Although stent thrombosis is infrequent in the modern era, it can be fatal (incidence of 20%–40%) or, in those who survive, may result in increased need for revascularization. In addition to adversely impacting clinical outcomes, it imposes a significant financial burden on the health care system. In a retrospective study (3,295 stent procedures) the median total hospital cost to treat a stent thrombosis...
was $11,134 per patient (2000 US dollars).

In a study done on selected elderly US Medicare patients undergoing PCI, for each patient who underwent repeat revascularization, one-year follow-up medical costs increased by >$19,000 (2004 US dollars) per patient, even after adjustment for differences in baseline patient characteristics. The key role played by platelets in pathologic thrombosis forms the basis for using various antplatelet agents in patients with ACS undergoing PCI. Aspirin, a thromboxane A2 inhibitor, when used alone has limited efficacy in preventing cardiovascular events after coronary stenting. This led to the development of potent antplatelet agents that block different pathways in platelet activation and aggregation, such as glycoprotein (GP) IIb/IIIa inhibitors and P2Y12 receptor blockers (Figure 1). Eptifibatide (Integrilin®; Schering-Plough, Kenilworth, NJ, USA), is one of three intravenous GP IIb/IIIa inhibitors approved for use in the US market, the others being abciximab (ReoPro®; Eli Lilly and Company, Indianapolis, IN, USA) and tirofiban (Aggrastat®; Medicure Inc., Winnipeg, MB, Canada). Basic pharmacologic differences between eptifibatide and other intravenous GP IIb/IIIa inhibitors are summarized in Table 1. The current review evaluates in detail the clinical and economic impact of using eptifibatide as an antplatelet agent in coronary stenting.

Pharmacodynamic evaluation

Biological properties

Eptifibatide is a synthetic cyclic heptapeptide that contains a lysine–glycine–aspartic acid sequence and resembles hemo-

dxin in the venom of the southern pygmy rattlesnake. It is a reversible competitive antagonist that binds to the active site of GP IIb/IIIa receptor and prevents platelet aggregation. It prevents binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa receptors. In order to inhibit platelet aggregation effectively, 80% of GP IIb/IIIa function needs to be blocked. It has very high affinity for the GP IIb/IIIa receptor compared with abciximab and tirofiban, with a dissociation constant of 120 nM. It also has a rapid onset and short duration of action. Peak plasma concentration is reached in 5 minutes and it has a half-life of 2.5–2.8 hours. Maximum inhibition of platelet aggregation occurs in 15 minutes and inhibition returns to 50% of baseline at 4 hours after drug cessation. Eptifibatide and its metabolites are primarily eliminated by the kidneys. The first step in metabolism is deamination, which makes a metabolite that was 41% of the platelet inhibitory effect of the primary compound. Therefore, a 50% dose reduction is recommended in patients with creatinine clearance less than 50 mL per minute, and eptifibatide is contraindicated in patients undergoing hemodialysis.

**Figure 1** Platelet activation pathway and site of action of antplatelet agents.

**Notes:** Platelets are activated via several different membrane receptors, resulting in platelet adhesion and aggregation. When endothelium is injured, the subendothelium exposes von Willebrand factor that binds to GP Ib, causing platelet adhesion. Thrombin, TXA2, and ADP bind to the thrombin receptor, TXA2 receptor, and P2Y12 receptor, respectively. This causes an increase in intracellular calcium (Ca2+) and a decrease in cAMP, leading to platelet contraction and GP IIb/IIIa activation. Activated GP IIb/IIIa on adjacent platelets bind to fibrinogen (final common pathway) leading to platelet aggregation and thrombus formation.

**Abbreviations:** AA, arachidonic acid; COX-2, cyclo-oxygenase-2; cAMP, cyclic adenosine monophosphate; ADP, adenosine diphosphate; ASA, aspirin; UFH, unfractionated heparin; LMWH, low molecular weight heparin; TXA2, thromboxane A2; GP, glycoprotein; vWF, von Willebrand factor; TXA2R, thromboxane A2 receptor.
**Table 1** Basic pharmacologic characteristics of glycoprotein IIb/IIIa inhibitors

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Eptifibatide</th>
<th>Abciximab</th>
<th>Tirofiban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type</td>
<td>Synthetic cyclic heptapeptide</td>
<td>Fab fragment of chimeric human-murine monoclonal antibody</td>
<td>Synthetic nonpeptide</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>Small molecule (832 Da)</td>
<td>Large molecule (47.15 Da)</td>
<td>Small molecule (496 Da)</td>
</tr>
<tr>
<td>Plasma half-life</td>
<td>2.5–2.8 hours</td>
<td>10–30 minutes</td>
<td>1.2–2 hours</td>
</tr>
<tr>
<td>Receptor binding</td>
<td>Seconds</td>
<td>Minutes</td>
<td>Seconds</td>
</tr>
<tr>
<td>Elimination site</td>
<td>Renal ~50%</td>
<td>Spleen</td>
<td>Renal 65%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Biliary 25%</td>
</tr>
</tbody>
</table>

**Evolution of dosage regimen**

Eptifibatide is a small peptide that was approved by the US Food and Drug Administration in 1998. The first major clinical trial of eptifibatide, IMPACT-II (Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II), did not show improvement in clinical outcomes due to use of a lower bolus dose (135 µg/kg). The dose calculation was based on studies that overestimated inhibition of platelet aggregation. This occurred due to use of citrate-containing blood samples that lowered the calcium concentration. Calcium is needed for binding of fibrinogen to GP IIb/IIIa. Subsequently, in the PRIDE (Platelet aggregation and Receptor occupancy with Integrilin - a Dynamic Evaluation) trial, the protease inhibitor PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone) was used in vitro for anticoagulation instead of citrate. This showed that a bolus dose of eptifibatide180 µg/kg followed by infusion at a rate of 2 µg/kg/min consistently achieved >80% platelet aggregation inhibition.

**Use in coronary stenting**

The evidence for clinical use of eptifibatide in coronary stenting is best discussed in the setting of the following scenarios.

**ST-segment elevation myocardial infarction**

Studies of eptifibatide in patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI are summarized in Table 2.

**Prior to use of P2Y₁₂ receptor inhibitors**

Large randomized controlled trials addressing the clinical outcomes of using eptifibatide as adjunctive therapy prior to the use of P2Y₁₂ receptor inhibitors (clopidogrel, prasugrel, and ticagrelor) are lacking. In two small trials, ie, INTAMI (Integrilin in Acute Myocardial Infarction) and TITAN (Time to Integrilin Therapy in Acute Myocardial Infarction)-TIMI 34, early use of eptifibatide was associated with pre-PCI vessel patency but no significant difference in the rates of death, reinfarction, or stroke. However, neither trial was adequately powered to evaluate the relationship between administration of eptifibatide and clinical outcomes.

In the era of P2Y₁₂ receptor inhibitors

Upfront loading with a high-dose P2Y₁₂ receptor inhibitor became common practice in patients undergoing PCI. Subsequently, the incremental benefit of addition of GP IIb/IIIa inhibitors came under scrutiny. In ASSIST (A Safety and Efficacy Study of Integrilin-Facilitated PCI in STE elevation Myocardial Infarction), after administration of dual antplatelet therapy, patients were randomized to PCI with heparin plus eptifibatide or to PCI with heparin alone. Open-label eptifibatide was given as two boluses of 180 µg/kg followed by a continuous infusion of 2.0 µg/kg/min (1.0 µg/kg/min if glomerular filtration rate was <50 mL per minute) for 18 hours after PCI. No improvement in clinical outcomes was noted with eptifibatide plus heparin compared with heparin alone (6.47% versus 5.53%, respectively; 95% confidence interval 0.52–2.70).

In the era of newer anticoagulants

Subsequent to introduction of bivalirudin, a direct thrombin inhibitor that was shown to be safer than heparin plus GP IIb/IIIa inhibitors for PCI, the planned usage of GP IIb/IIIa inhibitors declined because of concern about increased bleeding complications. In the landmark HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial, anticoagulation using bivalirudin alone with provisional use of GP IIb/IIIa inhibitors (7%) was compared with heparin plus planned GP IIb/IIIa inhibitors (eptifibatide 46%). GP IIb/IIIa inhibitors were provisionally used for angiographic findings of no reflow or giant thrombus after PCI in the bivalirudin group. There was no significant difference in the composite endpoint of death, reinfarction, target vessel revascularization, or stroke at 30 days (5.4% versus 5.5%, P=0.95) or at one year (11.9% versus 11.9%, P=0.98). However, there was a reduction in major bleeding (4.9% versus 8.3%, P<0.001) in the bivalirudin group. The role of eptifibatide in primary PCI was subsequently reduced to provisional use, covered in detail in the Conclusion and place in therapy subsection.

**Unstable angina/NSTEMI and stable coronary artery disease**

Studies with eptifibatide in patients with unstable angina, non ST-segment elevation myocardial infarction (NSTEMI) or stable coronary artery disease undergoing PCI are summarized in Table 3.
## Table 2: Studies with eptifibatide in patients undergoing PCI in STEMI

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patients (n)</th>
<th>Prior antiplatelet drugs</th>
<th>Patient population</th>
<th>Study groups/dosage of eptifibatide (bolus + infusion)</th>
<th>Endpoints (P) = Primary endpoint</th>
<th>Endpoint results (eptifibatide versus placebo, P-value)</th>
<th>Bleeding endpoints (TIMI bleeding: eptifibatide versus placebo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTAMI22</td>
<td>102</td>
<td>ASA</td>
<td>STEMI undergoing PCI</td>
<td>Early eptifibatide 2×180 µg/kg + 2.0 µg/kg/min &gt;12–24 hours late or no eptifibatide</td>
<td>TIMI III patency prior to PCI (P)</td>
<td>Death at 30 days</td>
<td>Major: 10.6 versus 9.1%, P&lt;0.05</td>
</tr>
<tr>
<td>TITAN-TIMI 3411</td>
<td>343</td>
<td>ASA</td>
<td>STEMI undergoing primary PCI</td>
<td>Early eptifibatide 2×180 µg/kg + 2.0 µg/kg/min late or no eptifibatide</td>
<td>Pre-PCI TIMI corrected frame count (P)</td>
<td>Death at 30 days</td>
<td>Major: 1.7% versus 3.5%, P=NS Minor: 5.2% vs 4.2%, P=NS</td>
</tr>
<tr>
<td>ASSIST22</td>
<td>400</td>
<td>ASA, clopidogrel</td>
<td>STEMI undergoing primary PCI</td>
<td>Heparin + eptifibatide 2×180 µg/kg + 2.0 µg/kg/min –18 hours Heparin alone</td>
<td>Death, reinfarction, recurrent severe ischemia at 30 days (P)</td>
<td>77.5±32.2 versus 84.3±30.7, P=0.049 4.0% versus 2.8%, P=0.76 6.5% versus 5.3%, P=0.69</td>
<td>Major: 9.5% versus 5.5%, P=0.14 Minor: 12.9% versus 9.1%, P=0.21</td>
</tr>
<tr>
<td>HORIZONS-AMI13</td>
<td>3,602</td>
<td>ASA, clopidogrel</td>
<td>STEMI undergoing PCI</td>
<td>Heparin + planned GP IIb/IIIa inh (eptifibatide 45.6%) Bivalirudin + provisional GP IIb/IIIa inh (eptifibatide 3.2%)</td>
<td>Net clinical outcome and major bleeding complications (P)</td>
<td>12.1% versus 9.2%, P=0.005</td>
<td>Major: 5.0% versus 3.1%, P=0.002 Minor: 4.6% versus 2.8%, P=0.006</td>
</tr>
<tr>
<td>EVA-AMI12</td>
<td>427</td>
<td>ASA, clopidogrel</td>
<td>STEMI undergoing PCI</td>
<td>Eptifibatide: 2×180 µg/kg + 2.0 µg/kg/min &gt;24 hours Abciximab: 0.25 mg/kg + 0.125 µg/kg/min</td>
<td>ST-segment resolution at 60 minutes after PCI (P)</td>
<td>Death/MI/TVR at 30 days 13.1% versus 10.0%, P=0.34 7.5% versus 8.5%, P=0.72</td>
<td>Major: 4.0% versus 2.0%, P=0.27 Minor: 12.4% versus 9.0%, P=0.28</td>
</tr>
</tbody>
</table>

**Abbreviations:** STEMI, ST-segment elevation myocardial infarction; TIMI, thrombosis in myocardial infarction; NS, not statistically significant; PCI, percutaneous coronary intervention; ASA, aspirin; inh, inhibitor; MI, myocardial infarction; TVR, target vessel revascularization; GP, glycoprotein.
<table>
<thead>
<tr>
<th>References</th>
<th>Patients (n)</th>
<th>Prior antiplatelet drugs</th>
<th>Patient population</th>
<th>Study groups/dosage of eptifibatide (bolus + infusion/duration)</th>
<th>Endpoints (P) = primary endpoint</th>
<th>Endpoint results (eptifibatide versus placebo, P-value)</th>
<th>Bleeding endpoints (TIMI bleeding) (eptifibatide versus placebo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMPACT-II 16</td>
<td>4,100</td>
<td>ASA</td>
<td>Elective, urgent, and emergent PCI</td>
<td>Eptifibatide 135 µg/kg + 0.5 µg/kg/min for 20–24 hours Eptifibatide 135 µg/kg + 0.75 µg/kg/min 20–24 hours Placebo</td>
<td>Death, MI, urgent, or emergency repeat coronary revascularization (P)</td>
<td>9.2% versus 9.9% versus 11.4% P = 0.063 (135/0.5) P = 0.22 (135/0.75)</td>
<td>Major: 5.1% versus 5.2% versus 4.8%</td>
</tr>
<tr>
<td>PURSUIT 25</td>
<td>10,948</td>
<td>ASA</td>
<td>ACS (PCI in 11.2%)</td>
<td>Eptifibatide 180 µg/kg + 2.0 µg/kg/min Placebo</td>
<td>Death or nonfatal MI at 30 days (P)</td>
<td>14.2% versus 15.7%, P = 0.04 11.6% versus 16.7%, P = 0.010</td>
<td>Minor: 11.1% versus 4.7%, P &lt; 0.001</td>
</tr>
<tr>
<td>ESPRIT 27</td>
<td>2,064</td>
<td>ASA, clopidogrel</td>
<td>Elective PCI and ACS (13%)</td>
<td>Eptifibatide 2 x 180 µg/kg + 2.0 µg/kg/min 18–24 hours Placebo</td>
<td>Death, MI, urgent TVR and bailout eptifibatide use at 30 days</td>
<td>6.6% versus 10.5%, P = 0.001</td>
<td>Major: 1.3% versus 0.4%, P = 0.027</td>
</tr>
<tr>
<td>EARLY ACS 50</td>
<td>9,492</td>
<td>ASA, clopidogrel</td>
<td>ACS undergoing invasive strategy (PCI in 59%)</td>
<td>Early eptifibatide: 2 x 180 µg/kg + 2.0 µg/kg/min ≥ 12 hours Placebo + delayed, provisional use of eptifibatide</td>
<td>Death, MI, recurrent ischemia requiring urgent revascularization or bailout eptifibatide at 96 hours (P)</td>
<td>9.3% versus 10.0%, P = 0.23 11.2% versus 12.3%, P = 0.079</td>
<td>Minor: 3.6% versus 1.7%, P &lt; 0.001</td>
</tr>
<tr>
<td>ACUITY 28</td>
<td>9,207</td>
<td>ASA, clopidogrel</td>
<td>Moderate to high risk ACS undergoing invasive strategy (PCI in 56.1%)</td>
<td>Routine upstream GP IIb/IIIa inh (eptifibatide in 61.5%) Deferred GP IIb/IIIa inh for PCI only Bivalirudin alone</td>
<td>Death, MI or unplanned revascularization at 30 days (P)</td>
<td>7.1% versus 7.9%, P = 0.044 P = 0.13</td>
<td>Major bleeding, non-CABG related: 6.1% versus 4.9%, P &lt; 0.001</td>
</tr>
<tr>
<td>REPLACE-2 29</td>
<td>6,010</td>
<td>ASA, thienopyridine</td>
<td>Urgent or elective PCI</td>
<td>Heparin + planned GP IIb/IIIa inh (eptifibatide in 53.4%) Bivalirudin + provisional GP IIb/IIIa inh (7.2% use)</td>
<td>Death, MI, urgent repeat revascularization or inhospital major bleeding at 30 days (P)</td>
<td>10.0% versus 9.2%, P = 0.32</td>
<td>Major bleeding: 4.1% versus 2.4%, P &lt; 0.001</td>
</tr>
<tr>
<td>PROTECT-TIMI 30 11</td>
<td>857</td>
<td>ASA, clopidogrel</td>
<td>Moderate to high-risk ACS undergoing PCI</td>
<td>Heparin + eptifibatide (2 x 180 µg/kg + 2.0 µg/kg/min 18–24 hours) Bivalirudin + provisional eptifibatide</td>
<td>Post-PCI coronary flow reserve (P)</td>
<td>1.33 versus 1.43, P = 0.036 8.8% versus 6.6%, P = 0.246</td>
<td>Major: 0.7% versus 0.0%, P = 0.308 Minor: 2.5% versus 0.4%, P = 0.027</td>
</tr>
<tr>
<td>BRIEF-PCI 38</td>
<td>624</td>
<td>ASA, clopidogrel (65.7%–70.8%)</td>
<td>Stable angina, ACS, or recent STEMI who underwent successful PCI</td>
<td>Eptifibatide 2 x 180 µg/kg + 2.0 µg/kg/min 18 hours Eptifibatide 2 x 180 µg/kg + 2.0 µg/kg/min &lt; 2 hours</td>
<td>Troponin-I &gt; 0.26 µg/L (P) Death, MI, or urgent TVR</td>
<td>28.3% versus 30.1%, P = 0.012 4.5% versus 4.8%, P = 1.0</td>
<td>Major: 4.2% versus 1.0%, P = 0.02 Minor: 21.2% versus 17.6%, P = 0.31</td>
</tr>
</tbody>
</table>

Note: *in patients who underwent early PCI.

Abbreviations: CAD, coronary artery disease; ACS, acute coronary syndrome; TIMI, thrombosis in myocardial infarction; NS, not statistically significant; PCI, percutaneous coronary intervention; ASA, aspirin; inh, inhibitor; MI, myocardial infarction; TVR, target vessel revascularization; GP, glycoprotein; NI, noninferiority; sup, superiority; STEMI, ST-segment elevation myocardial infarction; CABG, coronary artery bypass graft.
Prior to use of P2Y$_{12}$ receptor inhibitors
Prior to routine use of P2Y$_{12}$ receptor inhibitors, eptifibatide was studied in several randomized controlled trials. In the IMPACT-II trial (n=4,010), patients undergoing elective, urgent, or emergent PCI were given a lower bolus dose (135 µg/kg) followed by two different infusion rates (0.5 µg/kg/min or 0.75 µg/kg/min). At 30 days, the primary endpoint (death, myocardial infarction, or urgent revascularization) was reduced by an eptifibatide infusion of 0.5 µg/kg/min compared with placebo (9.1% versus 11.6%, P=0.035), with no significant difference seen at the higher infusion dose. These doses were felt to be at the lower end of the efficacy response curve. Hence, subsequent studies used a higher bolus dose of eptifibatide 180 µg/kg. In the PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) trial, eptifibatide (a single bolus of 180 µg/kg) significantly reduced death and nonfatal myocardial infarction (14.2% versus 15.7%, P=0.04) at 30 days compared with placebo. The benefit was more pronounced in patients who underwent early PCI (11.6% versus 16.7%, P=0.010). However, use of eptifibatide was associated with a higher incidence of bleeding and frequent blood transfusions.

In the era of P2Y$_{12}$ receptor inhibitors
In the ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy) trial, high-risk patients (age >75 years, with diabetes, elevated cardiac markers, STEMI within 7 days, or unstable angina within 48 hours of randomization) received a double dose of eptifibatide or placebo in a randomized, double-blind fashion prior to initiation of PCI. Both groups were pretreated with aspirin and a thienopyridine (either ticlopidine or clopidogrel). The primary endpoint (composite of death, myocardial infarction, urgent target vessel revascularization, and thrombotic bailout GP IIb/IIIa inhibitors within 48 hours after randomization) was reduced from 10.5% to 6.6% (P=0.0015) by eptifibatide when compared with placebo. The secondary endpoint of death, myocardial infarction, and urgent target vessel revascularization at 30 days was reduced from 10.5% to 6.8% (P=0.0034). Major bleeding was infrequent, but seen more often with eptifibatide (1.3% versus 0.4%, P=0.027).

In the era of newer anticoagulants
In the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial, 9,207 moderate to high-risk ACS patients were randomized to unfractionated heparin plus a GP IIb/IIIa inhibitor versus bivalirudin plus a GP IIb/IIIa inhibitor versus bivalirudin alone. In the subgroup analysis of patients undergoing PCI, addition of a GP IIb/IIIa inhibitor (eptifibatide use = 60%) to heparin did not improve the composite ischemic outcome (8% versus 9%, P=0.45) but significantly increased major bleeding (7% versus 4%, P<0.0001) when compared with bivalirudin alone. Similar results were seen in the REPLACE (Randomized Evaluation in PCI Linking Angioplasty to Reduced Clinical Events)-2 trial, in which heparin plus planned GPI IIb/IIIa inhibitors (53.4% received eptifibatide) during PCI was no different to bivalirudin plus provisional use (7.2%) of GP IIb/IIIa inhibitors with regard to the acute ischemic endpoint (10% versus 9.2%, P=0.32) but was associated with increased bleeding (4.1% versus 2.4%, P<0.001). In the PROTECT (Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet and Anti-Thrombotic Agents)-TIMI 30 trial, 857 patients with moderate to high-risk ACS undergoing PCI were randomized to heparin plus planned eptifibatide versus bivalirudin plus provisional eptifibatide. The primary endpoint of post-PCI coronary flow reserve was higher in the bivalirudin group (1.43 versus 1.33, P=0.036) with no significant difference in death or myocardial infarction at 48 hours. Although no difference in incidence of major REPLACE-2-type bleeding was seen, the incidence of minor bleeding was higher in the heparin plus eptifibatide group. Thus, eptifibatide plus heparin is no different in efficacy to bivalirudin, but is associated with a higher risk of bleeding.

Eptifibatide versus other GP IIb/IIIa inhibitors
Differences in cardiovascular outcomes were noted between the different GP IIb/IIIa inhibitors; however, evidence to suggest the superiority of eptifibatide over other GP IIb/IIIa inhibitors or vice versa is lacking. In the EVA-AMI (Eptifibatide Versus Abciximab in Primary PCI for Acute Myocardial Infarction) trial, which had a noninferiority design and enrolled 427 patients undergoing primary PCI, eptifibatide was as effective and safe as abciximab with respect to myocardial perfusion and clinical events. In the Swedish Coronary Angiography and Angioplasty Registry, comparison of STEMI patients undergoing primary PCI receiving either eptifibatide or abciximab (n=11,479) was done with a prespecified noninferiority margin set at 1.29. Eptifibatide was shown to be noninferior to abciximab with respect to death or myocardial infarction at one year (odds ratio 0.94, 95% confidence interval 0.82–1.09). In a subset analysis of the HORIZONS-AMI trial using propensity score

---

*Therapeutics and Clinical Risk Management 2014:10*
matching, there was no statistically significant difference between abciximab and eptifibatide for major bleeding risk (hazard ratio 1.05, 95% confidence interval 0.78–1.41) or clinical efficacy (hazard ratio 0.96, 95% confidence interval 0.77–1.20) at 3 years.²⁴

**Bleeding risk and approaches to improve safety**

The bleeding risk with GP IIb/IIIa inhibitors is increased in women, older patients, and in those with renal deficiency.²⁵–³⁷ In patients with creatinine clearance ≤50 mL per minute, eptifibatide is recommended as a 180 µg/kg bolus administered immediately before initiation of PCI followed by a lower infusion rate of 1 µg/kg/min. A second 180 µg/kg bolus 10 minutes after the first bolus can be given. Eptifibatide is contraindicated in patients on hemodialysis.

**Bolus only/short infusion versus long infusion**

Currently eptifibatide is given as a continuous infusion for 18–24 hours after PCI. A new dose regimen of eptifibatide was explored in the BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial,³⁸ where a single bolus dose plus a truncated infusion (<2 hours) of eptifibatide was used in low-risk patients undergoing PCI and was found to have a similar incidence of death, myocardial infarction, and target vessel revascularization (not statistically significant), but with less incidence of major bleeding (1.0% versus 4.2%, \( P=0.02 \)). This trial showed that after a successful and uncomplicated PCI, the value of prolonged infusion is limited, especially in low-risk patients. Similar findings were noted in a retrospective study by Kini et al.,³⁹ where 2,629 patients who received either a GP IIb/IIIa inhibitor (72% eptifibatide) bolus plus infusion versus a GP IIb/IIIa inhibitor bolus only were compared. Patients receiving the bolus only had similar periprocedural and one-year ischemic outcomes, but with reduced vascular bleeding events compared with the bolus plus infusion. Additionally, bolus only increased ambulatory PCI and reduced the length of stay. One could speculate that there may be a role for eptifibatide with bolus only/truncated infusion in the bivalirudin era. This could be substantiated by the argument that despite thienopyridine pretreatment, a large proportion of patients do not have optimal platelet inhibition during PCI.⁴⁰,⁴¹ However, the above studies included low-risk patients, and there is a need for larger trials exploring this dosage regimen in high-risk patients, in whom GP IIb/IIIa inhibitor use is most beneficial.

**Routine upstream versus delayed selective use**

The optimal timing of administration of eptifibatide was unclear. Whether upstream versus deferred/or delayed (at the time of PCI) had an effect on outcomes was explored in a few randomized controlled trials. In the EARLY ACS trial (ClinicalTrials.gov identifier NCT00089895),⁴² 9,492 patients with high-risk ACS undergoing an invasive strategy (59% underwent PCI) were studied to determine if routine early eptifibatide use was superior to provisional delayed use at the time of PCI. Eptifibatide infusion was given for 18–24 hours after PCI in both groups. No significant difference in the primary endpoint was noted between the early eptifibatide group and the delayed eptifibatide group (9.3% versus 10.0%, respectively, \( P=0.23 \)). However, patients in the early eptifibatide group had significantly higher TIMI major (2.6% versus 1.8%, \( P=0.015 \)) and minor (3.6% versus 1.7%, \( P<0.001 \)) bleeding. In the ACUITY trial,⁴³ patients on GP IIb/IIIa inhibitor therapy (61.5% of patients of the routine upstream group received eptifibatide) were further randomized to routine upstream versus deferred selective use. There was no significant difference in the rate of the composite endpoint of death, myocardial infarction, or unplanned revascularization for ischemia between routine upstream use compared with deferred selective use of a GP IIb/IIIa inhibitor (7.1% versus 7.9%; \( P=0.044 \) for noninferiority, \( P=0.13 \) for superiority). However, deferred therapy was associated with significantly less major bleeding at 30 days (4.9% versus 6.1%, \( P<0.001 \)). Thus, in patients pretreated with \( \text{P2Y}_{_12} \) inhibitors, upstream use of eptifibatide is associated with increased bleeding risk and should be avoided.

**Radial versus femoral access**

Radial access may obviate the bleeding risk associated with GP IIb/IIIa inhibitors. In a subgroup analysis of the ACUITY trial, the advantage of reduction of major bleeding seen with bivalirudin monotherapy over heparin plus GP IIb/IIIa inhibitors (eptifibatide 60%) was no longer significant when radial access was used (4.2% versus 2.2%, \( P=0.19 \)).⁴⁴ In a single-center, prospective, registry study performed in the UK,⁴⁵ consecutive patients undergoing primary PCI with unfractionated heparin plus eptifibatide via radial access were enrolled and compared with the bivalirudin arm of the HORIZONS-AMI trial. In the subgroup of patients fulfilling the HORIZONS-AMI entry criteria, major bleeding was no different to that in the bivalirudin arm of HORIZONS-AMI (3.7% versus 4.9%, \( P=0.32 \)). This observation is noteworthy because the registry consisted of patients with a high bleeding
risk and unselected STEMI, who were pretreated with a thienopyridine prior to primary PCI. A Canadian study\(^46\) that propensity-matched 3,198 patients undergoing PCI via radial access to 3,198 patients undergoing PCI via femoral access (80% unfractionated heparin with epifibatide use in both groups) showed that radial access was an independent predictor of fewer access site complications (odds ratio 0.39, 95% confidence interval 0.2–0.7). Thus, further studies comparing unfractionated heparin plus epifibatide with newer anticoagulants in patients undergoing PCI via radial access may be warranted.

**Pharmacoeconomic evaluation**

Cost-effectiveness data for routine addition of epifibatide to unfractionated heparin coming from evaluation of larger randomized controlled trials may not necessarily reflect “real-world” costs. In a prospective economic study\(^37\) of patients enrolled in the PURSUIT trial, the incremental cost-effectiveness ratio for routine addition of epifibatide to unfractionated heparin in the US cohort of PURSUIT patients was $16,491 (1996 US dollars) per year of life saved, and the cost–utility ratio for epifibatide was $19,693 per added quality-adjusted life-year. Eptifibatide was felt to be economically attractive for usual care of NSTEMI by conventional standards. In an economic analysis\(^48\) of the ESPRIT trial (US cohort), the acquisition cost of epifibatide was offset by reduced medical resource consumption during the initial hospitalization period (by 40%) and over a one-year period (by 70%). In the real-world retrospective analysis, similar results with epifibatide were seen. In a retrospective US cost-effectiveness analysis that incorporated data from the ESPRIT trial and modeled life expectancy using a large cardiovascular database, epifibatide was associated with a favorable cost-effectiveness ratio of $1,407 (2000 US dollars) per life-year gained. The cost-effectiveness of adding epifibatide to unfractionated heparin for selected high-risk patients undergoing PCI in Germany was studied by Dewilde et al.\(^49\) They showed that while epifibatide was an additional expense initially, it recovers its cost by avoiding costly repeat procedures and preventing cardiovascular events, leading to positive quality-adjusted life-year gains. The incremental net benefit of its use exceeded €10,000 (about $13,000 in 2006 US dollars) from a hospital and a third-party payer perspective.

Among the GP IIb/IIIa inhibitors, epifibatide was seen to be more economically attractive. The PRICE (Prairie ReoPro versus Integrilin Cost Evaluation) trial\(^50\) compared the overall hospital costs of epifibatide and abciximab in patients undergoing elective PCI. While inhospital and 30-day composite outcomes (death, nonfatal myocardial infarction, and urgent revascularization) were similar (5.6% versus 6.3%, \(P=0.95\)), the median inhospital cost (1999/2000 US dollars) with epifibatide ($7,207, interquartile range $5,659, $9,307) was lower than with abciximab ($8,268, interquartile range $6,505, $9,958). This difference was sustained even at 30 days. In a retrospective cohort analyses of outcomes and costs between abciximab and epifibatide, comparable outcomes for safety and effectiveness were seen, but the total costs for hospitalization ($16,383±6,799 versus $14,115±6,285, \(P<0.001\)) and drug acquisition costs ($508±159 versus $465±263, \(P=0.003\)) were greater for abciximab than for epifibatide.\(^31\) In a review of published data from 1994 to 2002 in the setting of PCI, Le Pen et al\(^52\) noted that epifibatide had lower acquisition and treatment costs compared with abciximab. However, if cost was weighted by clinical trials, the difference disappeared or even reversed. They concluded that the concept of cost, inevitably entering into the choice of a medical strategy, must be used with caution. The cost implications in TRANSFER-AMI (Trial of Routine ANgioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction)\(^53\) were studied by Bagai et al.\(^54\) The TRANSFER-AMI trial randomized 1,059 high-risk patients with STEMI to routine early PCI or PCI only for failed fibrinolysis. There was high and similar usage of GP IIb/IIIa inhibitors in both groups (83.6% versus 81.2%, \(P=0.39\)). At one year, there was no difference in death or reinfarction (10.3% versus 11.6%, \(P=0.50\)). In the cost analysis, the routine early PCI group had a higher cost (2008 US dollars) per patient (difference $1,003, 95% confidence interval −247, 2,211) and this was driven mainly by air transportation and higher use of abciximab than epifibatide (2:1 compared with 4:5 in PCI only for failed fibrinolysis). Further analysis showed that if epifibatide was used primarily, drug costs would be lower by $300 per patient, reducing the overall difference in study costs between routine early PCI and PCI only for failed fibrinolysis from $1,003 to $629. Additionally, in a scenario where land-only transportation and use of epifibatide was taken, difference in costs between routine early PCI and PCI only for failed fibrinolysis reduced from $1,003 to as low as $108.

With the advent of bivalirudin alone as an option for anticoagulation after PCI, routine addition of epifibatide to unfractionated heparin was not economically viable due to higher acquisition costs and costs related to bleeding complications. Economic evaluation of the REPLACE-2 trial\(^55\) showed that routine epifibatide plus unfractionated heparin
increased in-hospital and 30-day costs (2002 US dollars) by $405 and $374, respectively. In a cost-effectiveness analysis of the REPLACE-2 trial and three other randomized controlled trials, bivalirudin with provisional GP IIb/IIIa inhibitors was shown to be more cost-effective than unfractionated heparin with planned GP IIb/IIIa inhibitors. However, sensitivity analyses revealed that unfractionated heparin with eptifibatide was more cost-effective if two or more vials of bivalirudin were used (27% of the cases) or provisional use of GP IIb/IIIa inhibitors exceeded 20%. Additionally, unfractionated heparin with eptifibatide was better than abciximab ($74 more expensive and 1.2% less effective versus $777 more expensive and 2.3% less effective). Among US patients in the ACUITY trial, unfractionated heparin plus a GP IIb/IIIa inhibitor during PCI was associated with $200 (2005 US dollars) lower initial hospital stay net cost savings compared with bivalirudin alone. This was primarily due to more major and minor bleeding associated with GP IIb/IIIa inhibitors. A higher baseline risk of bleeding confers a higher absolute benefit of any therapy associated with a fixed relative risk reduction of bleeding as seen with bivalirudin. Therefore, the favorable cost-effectiveness seen with bivalirudin in the above trials and other studies might be overestimated given that routine use of eptifibatide has declined in the real world, along with the associated bleeding risk. In addition, potential adaptation of further strategies, such as radial access PCI that reduces the bleeding risk, may further decrease the cost difference.

The efficacy, safety, and cost of high-dose (20 mg) single bolus eptifibatide was studied by Fischell et al as an alternative to a conventional double bolus plus intravenous infusion regimen during elective PCI. The primary endpoint was similar to that of the ESPRIT and REPLACE-2 trials, and the average per patient cost of anticoagulation was $66. In perspective, the respective costs of eptifibatide and bivalirudin were $930 and $530 (2006 US dollars) in the REPLACE-2 trial. However, this was an observational registry study without a control arm and the patients were not a high-risk ACS group where the benefit of a GP IIb/IIIa inhibitor is greatest. More studies of the efficacy and cost-effectiveness of this dosing regimen should be done in the future.

Conclusion and place in therapy

Antiplatelet therapy in patients undergoing PCI for ACS has been shown to reduce major adverse cardiovascular events. Aggressive platelet inhibition can be achieved by eptifibatide, which differs in its pharmacologic properties from other GP IIb/IIIa inhibitors. While no large randomized controlled trials were done to compare eptifibatide with other agents, equivalent efficacy was seen in indirect analyses. The role of eptifibatide in the contemporary era, where pretreatment with dual antiplatelet therapy and use of newer safer anticoagulants (especially bivalirudin) at the time of PCI is routine practice, has become more refined and can be best elucidated in select clinical situations (Table 4). Delayed use (at the time of PCI) is recommended if pretreated with P2Y<sub>12</sub> receptor inhibitor. However, if bivalirudin is being used as the primary anticoagulant during PCI, routine use of eptifibatide is not recommended but may be considered if there are angiographic complications. In patients with unstable angina/NSTEMI and stable

### Table 4 American College of Cardiology/American Heart Association guidelines (modified) for use of eptifibatide in patients undergoing PCI

<table>
<thead>
<tr>
<th>STEMI</th>
<th>It is reasonable to begin treatment with double-bolus eptifibatide as the time of primary PCI (with or without stenting or clopidogrel pretreatment) in selected patients with STEMI who are receiving UFH.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class IIa&lt;sup&gt;a&lt;/sup&gt;</td>
<td>It may be reasonable to administer eptifibatide in the precatheterization laboratory setting (eg, ambulance, ED) to patients with STEMI for whom primary PCI is intended.</td>
</tr>
<tr>
<td>Class IIb&lt;sup&gt;b&lt;/sup&gt;</td>
<td>In high-risk patients treated with UFH and adequately pretreated with clopidogrel, it is reasonable at the time of PCI to administer eptifibatide.</td>
</tr>
<tr>
<td>Class III: No benefit</td>
<td>Eptifibatide should not be administered to patients in whom PCI is not planned.</td>
</tr>
<tr>
<td>Stable CAD</td>
<td>In patients undergoing elective PCI treated with UFH and not pretreated with clopidogrel, it is reasonable to administer eptifibatide.</td>
</tr>
<tr>
<td>Class IIa&lt;sup&gt;c&lt;/sup&gt;</td>
<td>In patients undergoing elective PCI with stent implantation treated with UFH and adequately pretreated with clopidogrel, it might be reasonable to use eptifibatide.</td>
</tr>
</tbody>
</table>

Notes: <sup>a</sup>Recommendation that procedure or treatment is useful/effective; <sup>b</sup>recommendation in favor of treatment or procedure being useful/effective; <sup>c</sup>recommendation’s usefulness/effectiveness less well established; <sup>d</sup>data derived from a single randomized trial or nonrandomized studies; <sup>e</sup>data derived from multiple randomized clinical trials or meta-analysis.

Abbreviations: PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; UFH, unfractionated heparin; ED, emergency department; UA, unstable angina; NSTEMI, non ST-segment elevation myocardial infarction; CAD, coronary artery disease.
coronary artery disease undergoing PCI, the data suggest a benefit of deferred (at the time of PCI) use of eptifibatide in high-risk NSTEMI patients who are not being treated with bivalirudin for anticoagulation; however, the bleeding risk needs to be considered. If bivalirudin is being used at the time of PCI and at least 300 mg of clopidogrel is given at least 6 hours prior to PCI, routine use of a GP IIb/IIIa inhibitor could be omitted. In patients with unstable angina/ NSTEMI already receiving aspirin and a P2Y₁₂ inhibitor, consider upstream use only in high-risk (elevated troponin levels, diabetes, or significant ST-segment depression) patients selected for an invasive strategy and not otherwise at high risk for bleeding.⁶⁴

Pharmacoeconomics are favorable to eptifibatide when compared with other GP IIb/IIIa inhibitors. However, in the contemporary era of P2Y₁₂ inhibitors and bivalirudin, routine use of eptifibatide is not economically viable, mainly because of the increased costs associated with bleeding complications. The cost-effectiveness of eptifibatide when strategies that decrease the bleeding risk like transradial PCI are used is unknown. Single bolus eptifibatide with a truncated infusion regimen may offset some of the increased costs; however, this needs to be explored in larger trials in the future.

Future studies could focus on finding a sweet spot for the risk-benefit and cost-effectiveness of eptifibatide in patients undergoing PCI. Single bolus plus truncated infusion and preferential use in clopidogrel nonresponders⁶⁶ could be potential therapeutic options. With the advent of newer antiplatelet agents with a rapid onset of action, the role of eptifibatide needs to be defined further.⁶⁷,⁶⁸

In summary, eptifibatide is a potent, short-acting, intra- venous antiplatelet agent with a rapid onset of action. There is good evidence that eptifibatide is an effective adjunct to unfractionated heparin in high-risk patients undergoing PCI, where the benefit would outweigh the risk of bleeding. Eptifibatide has an important but selective role in the era of dual antiplatelet therapy, newer safer anticoagulants, and contemporary PCI.

Disclosure
The authors report no conflicts of interest in this work.

References


